| P50 | author | John D. Imig | Q42333739 |
| | Md Abdul Hye Khan | Q42808039 |
| P2093 | author name string | John D Imig | |
| | Abdul Hye Khan | |
| P2860 | cites work | Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 |
| | Insulin and insulin resistance: impact on blood pressure and cardiovascular disease | Q28167207 |
| | Management of the metabolic syndrome | Q28208797 |
| | Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension | Q28390972 |
| | Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma | Q28567488 |
| | Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet | Q30482887 |
| | Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats | Q33742301 |
| | Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity | Q33976477 |
| | HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats | Q34099442 |
| | Attitudes of preclinical medical students towards caring for chronically ill and dying patients: does palliative care teaching make a difference? | Q35561740 |
| | Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance | Q35636695 |
| | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence | Q35641628 |
| | Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells | Q35773071 |
| | Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases | Q35867207 |
| | ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects | Q35868228 |
| | Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. | Q37174513 |
| | Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation | Q37184165 |
| | Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity | Q42829351 |
| | Induction of hemeoxygenase-1 attenuates the hypertension and renal inflammation in spontaneously hypertensive rats | Q42953520 |
| | Comparison of purple carrot juice and β-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome | Q42974751 |
| | Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet | Q43262113 |
| | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats | Q43277441 |
| | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect | Q44090671 |
| | Renal processing of albumin in diabetes and hypertension in rats: possible role of TGF-beta1. | Q44248387 |
| | Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes | Q44758853 |
| | Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats | Q44986827 |
| | Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. | Q45038781 |
| | Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. | Q45249894 |
| | Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. | Q45915450 |
| | Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan | Q46167652 |
| | Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis | Q46191945 |
| | Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers | Q46467059 |
| | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy | Q46616440 |
| | Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program | Q46873807 |
| | Interactions between oxidative stress and inflammation in salt-sensitive hypertension. | Q46962281 |
| | Effects of pioglitazone on increases in visceral fat accumulation and oxidative stress in spontaneously hypertensive hyperlipidemic rats fed a high-fat diet and sucrose solution | Q46965578 |
| | Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. | Q53312680 |
| | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors | Q79326169 |
| | Telmisartan, its potential therapeutic implications in cardiometabolic disorders | Q80551161 |
| | Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats | Q80609679 |
| P433 | issue | 7 | |
| P921 | main subject | metabolic syndrome | Q657193 |
| P304 | page(s) | 816-821 | |
| P577 | publication date | 2011-03-17 | |
| P1433 | published in | Journal of Clinical Hypertension | Q15762840 |
| P1476 | title | Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome | |
| P478 | volume | 24 | |